Delta-Fly Pharma, Inc.
4598 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 徳島市川内町宮島錦野３７番地の５
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Delta-Fly Pharma, Inc. is a Japanese biopharmaceutical company focused on innovative drug development through its modular approach. The company emphasizes a philosophy rooted in cutting-edge research and a commitment to advancing health solutions. Delta-Fly Pharma’s robust pipeline showcases its dedication to discovering and developing novel therapies. With a strong emphasis on licensing opportunities, the company collaborates with partners to enhance its research capabilities and expand its reach in the pharmaceutical market. Through presentations and publications, Delta-Fly Pharma actively shares its findings and insights, contributing to the global scientific community and striving to improve patient outcomes worldwide.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-27 08:44 |
Inside Information Statement
臨時報告書
|
Japanese | 24.4 KB | |
| 2025-06-27 08:39 |
Internal Control over Financial Reporting
内部統制報告書－第15期(2024/04/01－2025/03/31)
|
Japanese | 23.0 KB | |
| 2025-06-27 08:34 |
Regulatory News Service
確認書
|
Japanese | 8.8 KB | |
| 2025-06-27 08:30 |
Annual Report
有価証券報告書－第15期(2024/04/01－2025/03/31)
|
Japanese | 1.1 MB | |
| 2025-04-14 08:30 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 289.0 KB | |
| 2024-11-14 07:39 |
Regulatory News Service
確認書
|
Japanese | 8.9 KB | |
| 2024-11-14 07:36 |
Interim Report
半期報告書－第15期(2024/04/01－2025/03/31)
|
Japanese | 180.2 KB | |
| 2024-10-07 08:00 |
Inside Information Statement
臨時報告書
|
Japanese | 22.6 KB | |
| 2024-09-20 08:00 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 326.2 KB | |
| 2024-09-11 08:00 |
Inside Information Statement
臨時報告書
|
Japanese | 22.8 KB | |
| 2024-06-28 08:31 |
Inside Information Statement
臨時報告書
|
Japanese | 23.5 KB | |
| 2024-06-28 08:28 |
Regulatory News Service
確認書
|
Japanese | 8.8 KB | |
| 2024-06-28 08:25 |
Internal Control over Financial Reporting
内部統制報告書－第14期(2023/04/01－2024/03/31)
|
Japanese | 22.6 KB | |
| 2024-06-28 08:21 |
Annual Report
有価証券報告書－第14期(2023/04/01－2024/03/31)
|
Japanese | 979.5 KB | |
| 2024-02-13 07:20 |
Regulatory News Service
確認書
|
Japanese | 8.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Nippon Shinyaku Co.,Ltd. | Japan | 4516 | |
|
Noile-Immune Biotech Inc. | Japan | 4893 | |
|
Novartis AG | Switzerland | NOVN | |
|
Nur Ink Innovations Ltd. | Israel | NURI | |
|
Nxera Pharma Co., Ltd. | Japan | 4565 | |
|
ObsEva SA | Switzerland | OBSN | |
|
ODI Pharma AB | Sweden | ODI | |
|
Oncolys BioPharma Inc. | Japan | 4588 | |
|
OncoTherapy Science, Inc. | Japan | 4564 | |
|
OncoZenge AB | Sweden | ONCOZ |